Recent Insider Transactions • Mar 21
Chairman & MD recently bought €27m worth of stock On the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Feb 05
ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million. ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife. Announcement • Nov 11
AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid Price On November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard. Breakeven Date Change • Nov 08
No longer forecast to breakeven The 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024. Reported Earnings • Nov 04
Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021) Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Announcement • Oct 18
Alerislife Inc. Appoints Philip Benjamson as Senior Vice President and Chief Operating Officer The Board of Directors of AlerisLife Inc. (the “Company”) has appointed Philip Benjamson as Senior Vice President and Chief Operating Officer of the Company, effective October 17, 2022. Prior to joining the Company, Mr. Benjamson, 55, served as Vice President-Senior Housing Operations at Trinity Health Senior Communities since May 2021. Prior to Trinity Health Senior Communities, Mr. Benjamson served as Chief Operating Officer at Resort Lifestyle Communities from July 2018 to May 2021 and at Blake Management Group from December 2016 to July 2018. Prior to those roles, Mr. Benjamson held several leadership roles in sales and marketing at senior living companies. Mr. Benjamson holds a Bachelor of Arts in Organizational Development from the University of California, Davis. Mr. Benjamson has advised the Company that he has no arrangements or understandings with any other person pursuant to which he was appointed Senior Vice President and Chief Operating Officer. He also advised the Company that he has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer of the Company. Announcement • Oct 06
AlerisLife Inc. to Report Q3, 2022 Results on Nov 02, 2022 AlerisLife Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 02, 2022 Breakeven Date Change • Aug 09
No longer forecast to breakeven The 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024. Reported Earnings • Aug 05
Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.39 loss in 2Q 2021) Second quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Over the next year, revenue is forecast to grow 389%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Announcement • Jul 07
AlerisLife Inc. to Report Q2, 2022 Results on Aug 03, 2022 AlerisLife Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 03, 2022 Reported Earnings • May 05
First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.10 profit in 1Q 2021) First quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Over the next year, revenue is forecast to grow 902%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Breakeven Date Change • Apr 27
Forecast breakeven date pushed back to 2024 The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule. Breakeven Date Change • Apr 07
Forecast breakeven date pushed back to 2024 The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule. Announcement • Apr 07
AlerisLife Inc., Annual General Meeting, Jun 07, 2022 AlerisLife Inc., Annual General Meeting, Jun 07, 2022, at 09:30 US Eastern Standard Time. Agenda: To consider the election of the Director nominees to Board of Directors; to consider the approval of the second amended and restated 2014 Equity Compensation Plan; to ratify the appointment of Deloitte & Touche LLP as independent auditors to serve for the 2022 fiscal year; and to transact such other business as may properly come before the meeting and at any postponements or adjournments of the meeting. Announcement • Apr 06
AlerisLife Inc. to Report Q1, 2022 Results on May 03, 2022 AlerisLife Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022 Recent Insider Transactions • Mar 05
Insider recently bought €91k worth of stock On the 1st of March, Lauren Cody bought around 40k shares on-market at roughly €2.27 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 329%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Announcement • Feb 02
AlerisLife Inc. to Report Q4, 2021 Results on Feb 23, 2022 AlerisLife Inc. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022 Reported Earnings • Nov 05
Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020) The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The 2 analysts covering Five Star Senior Living expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.15m in 2022. Average annual earnings growth of 120% is required to achieve expected profit on schedule. Reported Earnings • Aug 06
Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020) The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 06
Forecast breakeven pushed back to 2022 The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improved over the past week After last week's 18% share price gain to US$5.10, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 28x in the Healthcare industry in Germany. Total loss to shareholders of 49% over the past three years. Reported Earnings • May 07
First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 04
New 90-day low: €5.20 The company is down 1.0% from its price of €5.25 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 9.0% over the same period. Executive Departure • Mar 02
Chief Accounting Officer has left the company On the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (€14k worth at the time). Ellen is the only executive to leave the company over the last 12 months. Reported Earnings • Feb 27
Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019) The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$221.9m (down 80% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improved over the past week After last week's 16% share price gain to US$6.75, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32.9x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 44%. Is New 90 Day High Low • Feb 06
New 90-day high: €6.75 The company is up 70% from its price of €3.98 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period. Announcement • Feb 02
Five Star Senior Living Inc. Partners with CVS to Administer Vaccines to Shop Community Residents and Staff, Which Commenced in December 2020 Five Star Senior Living Inc. has partnered with CVS to administer vaccines to SHOP community residents and staff, which commenced in December 2020. DHC expects vaccination clinics for SHOP community residents and staff to be substantially complete by the end of the first quarter of 2021. As it pertains to DHC’s SHOP segment, as of January 29, 2021. Approximately 18,000 total residents and staff, or more than 65% of residents and more than 30% of staff at DHC’s SHOP communities, have received vaccinations. This includes over 2,000 residents and staff who have received both doses of the vaccine; Approximately 93% of DHC’s SHOP communities are currently open to new admissions; and; Approximately 3.5% of DHC’s total SHOP community residents have or have had active cases of COVID-19, and approximately 67% of those who have tested positive for COVID-19 during the pandemic have since recovered, as defined by CDC guidelines. For the months ended September 30, October 31, November 30 and December 31, 2020, average occupancies in DHC’s SHOP segment were 74.5%, 73.8%, 72.5%, and 70.7%, respectively. Although occupancy has declined because of reduced move-ins by residents, sales leads have increased substantially since the end of 2020. The rolling four-week average sales leads as of January 24, 2021 were 83% higher than the rolling four-week average sales leads at the beginning of the fourth quarter of 2020. Announcement • Jan 29
Five Star Senior Living Inc. to Report Q4, 2020 Results on Feb 24, 2021 Five Star Senior Living Inc. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021 Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improved over the past week After last week's 16% share price gain to US$6.65, the stock is trading at a trailing P/E ratio of 35.7x, up from the previous P/E ratio of 30.9x. This compares to an average P/E of 17x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 46%. Is New 90 Day High Low • Dec 12
New 90-day high: €6.05 The company is up 33% from its price of €4.54 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period. Valuation Update With 7 Day Price Move • Dec 08
Market bids up stock over the past week After last week's 19% share price gain to US$5.85, the stock is trading at a trailing P/E ratio of 31.4x, up from the previous P/E ratio of 26.3x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%. Valuation Update With 7 Day Price Move • Dec 05
Market bids up stock over the past week After last week's 15% share price gain to US$5.65, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27.5x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%. Is New 90 Day High Low • Nov 24
New 90-day high: €4.60 The company is up 5.0% from its price of €4.38 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. Valuation Update With 7 Day Price Move • Nov 12
Market bids up stock over the past week After last week's 18% share price gain to US$4.42, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 70%. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS US$0.12 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 29
New 90-day low: €3.74 The company is down 1.0% from its price of €3.78 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 15% over the same period. Announcement • Oct 10
Five Star Senior Living Inc. to Report Q3, 2020 Results on Nov 05, 2020 Five Star Senior Living Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 05, 2020 Announcement • Jul 10
Five Star Senior Living Inc. to Report Q2, 2020 Results on Aug 06, 2020 Five Star Senior Living Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 06, 2020 